Abstract:OBJECTIVE:Numerous studies in children with growth hormone deficiency (GHD) show that recombinant human growth hormone (rhGH) treatment results in significant catch-up growth, but some papers reported that the children who underwent rhGH therapy might be at increased risk of diabetes. The aim of this study was to investigate the effects of rhGH treatment on blood glucose and insulin metabolism in children with GHD and the relationship between growth hormone (GH) and glucose homeostasis.METHODS:In this study, 44 children with GHD treated with rhGH [0.1 U/(kgxd)] and age- and sex-matched 20 healthy children were enrolled. The GHD group included 28 males and 16 females aged from 4.5 to 16.5 years (mean 10.4 +/- 2.6 years), including 18 cases of complete GHD and 26 cases of partial GHD. The sexual development stage of all subjects was in Tanner I. Oral glucose tolerance tests (OGTT) were done, and body mass index (BMI), serum insulin-like growth factor-1 (IGF-1) level and insulin resistance by homeostasis model (HOMA-IR) were measured at the time of diagnosis and every 3 months after rhGH therapy. Continuous glucose monitoring system (CGMS) was applied for two cases with hyperglycemia.RESULTS:(1) Fasting glucose and IGF-1 levels increased since 3 months of treatment and did not decrease since then. The levels of fasting glucose and IGF-1 at every time points of rhGH therapy were higher than the levels at the time of diagnosis (F = 6.81, P < 0.01; F = 7.31, P < 0.01, respectively). HOMA-IR and fasting insulin levels were increased since 3 and 9 months of treatment (P = 0.001 and P = 0.021, respectively). They decreased after 12 months of therapy and the levels at 18 months of therapy were similar to that at diagnosis. (2) Pearson correlation analysis showed that HOMA-IR was positively correlated with BMI, IGF-1 and the duration of treatment (r = 0.251, 0.437, 0.281, P < 0.01, respectively). The curve between HOMA-IR and duration of therapy was similar with parabola and the quadratic equation obtained was as follows: HOMA-IR = 1.5048 + 0.2177 x duration of therapy (months)-0.0103 x duration of therapy (months)(2) (r(2) = 0.147, F = 14.16, P < 0.01). (3) Two cases had transitory hyperglycemia. Their fasting glucose levels were all higher than 7.1 mmol/L. The glucose levels returned to normal after 1 month and 5 days respectively. OGTT and CGMS showed that their plasma glucose levels were normal after rhGH therapy was applied again.CONCLUSION:The children who underwent rhGH therapy may be at increased risk of insulin resistance (especially during the first year) and the therapy may even induce transitory glucose metabolic disorder in a very small proportion of patients. Circulating IGF-1 may participate in the control of insulin sensitivity and play an important role in the hormonal balance between GH and insulin. It may be necessary to monitor glucose metabolism and IGF-1 for all children who are treated with rhGH therapy.

The Effect and Potential Mechanism Analysis of Growth Hormone-Secreting Pituitary Adenomas on Thyroid Function

Growth hormone-secreting pituitary adenoma combined with Graves' disease: retrospective case series and literature review

Uric acid levels correlate with disease activity in growth hormone-secreting pituitary adenoma patients

The Diagnosis and Treatment of Growth Hormone Secreting Pituitary Adenomas: Analysis of 95 Cases

Clinical Analysis of Adult Growth Hormone Deficiency on the Postoperative Patients with Pituitary Adenoma

The comprehensive impact on human body induced by resolution of growth hormone excess.

Growth hormone replacement may influence the biological action of thyroid hormone on liver and bone tissue

Clinical Features and Therapeutic Outcomes of GH/TSH Cosecreting Pituitary Adenomas: Experience of a Single Pituitary Center

Surgical Outcomes and Predictors of Glucose Metabolism Alterations for Growth Hormone-Secreting Pituitary Adenomas: a Hospital-Based Study of 151 Cases.

Effects of transsphenoidal surgery on anterior pituitary function in growth hormone-secreting pituitary adenomas and analysis of related factors

The effects of growth hormones on the growth velocities and serum index expressions in short stature children

Expression of growth hormone and its receptor in chronic atrophic gastritis and its clinical significance.

Surgical Results and Predictors of Initial and Delayed Remission for Growth Hormone-Secreting Pituitary Adenomas Using the 2010 Consensus Criteria in 162 Patients from a Single Center

Characteristics of Glucose Metabolism in Patients with Pituitary Growth Hormone Secreting Adenomas and the Impact of Trans?sphenoid Surgery

Effect of Recombinant Human Growth Hormone on Glucose Metabolism in Children with Growth Hormone Deficiency

Growth Hormone (GH) Expression on Chronic Atrophic Gastritis Patients

Effects of high-dose recombinant human growth hormone treatment on IGF-1 and IGFBP-3 levels in idiopathic dwarfism patients

[A Clinical Analysis of Thyrotropin-Secreting Pituitary Adenomas in 20 Patients].

Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study

Insulin-like growth factor-1 deficiency caused by hepatocellular adenoma leads to growth arrest, primary amenorrhea and metabolic syndrome: a case report and 4 years follow up

Characteristics and Factors Influencing Hypothalamic Pituitary Dysfunction in Patients with Craniopharyngioma